featured
Factors Associated With Long-Term Outcomes of CD19 CAR T-Cell Therapy in Patients With Relapsed/Refractory CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Blood Adv 2023 Sep 29;[EPub Ahead of Print], EC Liang, A Albittar, JJ Huang, AV Hirayama, EL Kimble, AJ Portuguese, AG Chapuis, M Shadman, BG Till, RD Cassaday, F Milano, HP Kiem, SR Riddell, CJ Turtle, DG Maloney, J GauthierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.